HOTH (Hoth Therapeutics, Inc. Common Stock) Stock Analysis - News
Hoth Therapeutics, Inc. Common Stock (HOTH) is a publicly traded Healthcare sector company. As of May 21, 2026, HOTH trades at $0.60 with a market cap of $11.72M and a P/E ratio of -0.66. HOTH moved +0.10% today. Year to date, HOTH is -43.41%; over the trailing twelve months it is -29.07%. Its 52-week range spans $0.49 to $3.80. Rallies surfaces HOTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in HOTH news today?
Hoth Therapeutics Secures Spain Approval for HT-001 Phase 2a, Reports 65% Symptom Relief: Hoth Therapeutics secured Spanish regulatory approval for its randomized, placebo-controlled Phase 2a CLEER trial of HT-001 evaluating EGFR inhibitor skin toxicities. Interim data show rash severity reduced to ARIGA ≤1 by Week 6, over 65% of patients reported pain and itch relief, and no cancer therapy disruptions.
Knie Robb bought 25.00K (~$16.75K) on Aug 16, 2024.
Knie Robb bought 10.00K (~$3.90K) on Sep 19, 2022.
Knie Robb bought 10.00K (~$4.00K) on Sep 16, 2022.
HOTH Analyst Consensus
HOTH analyst coverage data. Average price target: $0.00.
Common questions about HOTH
What changed in HOTH news today?
Hoth Therapeutics Secures Spain Approval for HT-001 Phase 2a, Reports 65% Symptom Relief: Hoth Therapeutics secured Spanish regulatory approval for its randomized, placebo-controlled Phase 2a CLEER trial of HT-001 evaluating EGFR inhibitor skin toxicities. Interim data show rash severity reduced to ARIGA ≤1 by Week 6, over 65% of patients reported pain and itch relief, and no cancer therapy disruptions.
Does Rallies summarize HOTH news?
Yes. Rallies summarizes HOTH news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is HOTH research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HOTH. It does not provide personalized investment advice.
